$7.37
3.39%
Downside
Day's Volatility :6.32%
Upside
3.03%
73.41%
Downside
52 Weeks Volatility :80.34%
Upside
26.08%
Period | Humacyte Inc | |
---|---|---|
3 Months | 108.78% | |
6 Months | 182.38% | |
1 Year | 97.59% | |
3 Years | 104.72% |
Market Capitalization | 890.7M |
Book Value | $0.22 |
Earnings Per Share (EPS) | -1.0 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -36.66% |
Return On Equity TTM | -195.68% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.6M |
EBITDA | -93.6M |
Diluted Eps TTM | -1.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.99 |
EPS Estimate Next Year | -0.82 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.23 |
What analysts predicted
Upside of 8.55%
Sell
Neutral
Buy
Humacyte Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
BlackRock Inc
Vanguard Group Inc
Sio Capital Management, LLC
Geode Capital Management, LLC
State Street Corporation
Prescott Investors Inc
biotechnology company
Organization | Humacyte Inc |
Employees | 183 |
CEO | Dr. Laura E. Niklason M.D., Ph.D. |
Industry | Healthcare |